CERo Therapeutics Holdings, Inc. OQB · CERO
Price alert —
Sign in to get a one-time email the moment CERO crosses your price. Free accounts included.
Sign in / create a free accountCERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer.
CERO last traded at $0.01, down 8.3% on the day; that's in the lower part of its 52-week range ($0.01–$0.07). Right now it's trading close to its recent average, with no strong stretch in either direction.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and day to day, watch whether it holds above or slips below its recent average.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
below KC1 upper, -0.41 ATR from EMA21 — doji
- · Doji — indecision, watch for reversal
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · Doji — indecision, watch for reversal
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
CERO is a $0 million company, priced at 0× last year's earnings, and it moves more calmly than the market (beta 0.2); the stock is trading near the bottom of its 52-week range.
Earnings
See more →- Last reported
- 2025-11-19
- EPS (act / est)
- -9.10 / -4.35
- Surprise
- -109.2%
About
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco,…